|
|
Blood, Vol. 114, Issue 1, 144-147, July 2, 2009
Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies
Blood Abdel-Wahab et al.
114: 144
Supplemental materials for: Abdel-Wahab et al
Files in this Data Supplement:
- Table S1. Primer sequences and genomic coordinates of all amplicons sequenced in TET1, 2, 3 as well as MSP primers for TET2 (PDF, 60.8 KB)
- Table S2. Clinical characteristics and mutational status of 93 AML samples available for Kaplan Meier survival estimates (PDF, 141 KB)
- Table S3. Novel unannotated SNPs in TET1 and TET3 (PDF, 14.2 KB)
- Figure S1. Sequence traces of novel somatic missense mutation (A), unannotated single nucleotide polymorphism (B), nonsense mutation (C), and frameshift (D) (JPG, 515 KB)
-
Sequence trace from the tumor tissue and paired normal tissue from the same patient is displayed.
- Figure S2. Methylation status of TET2 promoter in (A) JAK2V617F-positive leukemia cell lines and (B) 37 MPN patient samples (JPG, 426 KB)
-
MSP was performed using primers specific for methylated and unmethylated sequences of 2 CpG-rich regions in the TET2 promoter. Only MSP data for the 2nd CpG region of TET2 is displayed for the MPN patient samples. Also shown are MSP performed in positive-control for methylation, in vitro methylated HCT116, and negative-control for methylation, DKO.
- Figure S3. Affymetrix 250K SNP array data revealing deletion of the region containing TET2 (4q24) in 3 samples out of 207 MPN samples (JPG, 427 KB)
-
Only one sample (sample 3) was noted to have a mutation of TET2 by bidirectional sequencing (mutation R1358C).
|
|
